Kinins—II pp 577-586 | Cite as

Autoreversal of Bradykinin Response in the Perfused Isolated Canine Hind Limb

  • Hans J. Wilkens
  • Nathan Back
Part of the Advances in Experimental Medicine and Biology book series (AEMB)


Bradykinin lowers the systemic arterial blood pressure in all animal species tested (Haddy, Emerson and others, 1970). This hypotensive effect of bradykinin es the result of a decrease in total peripheral resistance, most probably at the arteriolar level (Baez and Orkin, 1963). However, organ responses are not uniform but display a pattern of selective vasoconstriction and vasodilation (Arcidiacono, Reininger and Sapirstein, 1966). A constriction of larger veins has been observed in rat subcutaneous tissue (Rowley, 1964) and in the rabbit ear (Guth, Bobbin and others, 1966). Also the larger veins in the visceral area appear to be constricted strongly by bradykinin (Tsuru, Ishikawa and Shigei, 1974). Several authors have reported that isolated blood vessels and some vascular beds perfused with artificial fluids respond to bradykinin with constriction (Guth, Cano and Jamarillo, 1963; Moog and Fisher, 1964; Shimamoto, Numano and others, 1966; Wiegershausen, 1966; Northover, 1967). Other have observed a hypertensive response to bradykinin in nephrectomized rats, and in rats with low blood pressure (Croxatto and Belmar, 1961; Croxato, Belmar and others, 1962). Subsequently, it was reported by us that bradykinin elicits pressure increases in the blood-perfused isolated canine hind limb when injected after a large dose of histamine (Back and Wilkens, 1965). This finding was followed by our observation that bradykinin is a potent vasoconstrictor in the isolated canine hind limb when a small amount (3 mg %) of Polyox FRA, a commercially produced high molecular weight ethylene oxide polymer, is added to the circulating blood (Wilkens and Back, 1974). Since neither the vasoconstrictor action in the presence of Polyox FRA, nor the pressar effect following histamine could be abolished by alpha adrenergic blockade, we suggested that bradykinin might act on two types of receptors.


Perfusion Pressure Total Peripheral Resistance Hypotensive Response Systemic Arterial Blood Pressure Alpha Adrenergic Blockade 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arcidiacono, F.G. Reininger, E.J. and Sapirstein, L.A. (1967). 4th European Conference on Microcirculation, p. 29. Basel & New York: S. Karger.Google Scholar
  2. Ariens, E.J., Simonis, A.M. and Von R©ssum, J.M. (1964). Molecular Pharmacology. p. 293. New York & London: Academic Press.Google Scholar
  3. Back, N. and Wilkens, H.J. (1968). Pharmacology of Hormonal Polypeptides and Proteins, Eds. L. Martini, R. Paoletti and N. Back. p. 486. New York: Plenum Press.Google Scholar
  4. Baez, S. and Orkin, L.R. (1963). Anesthesiol, 24 568–579.Google Scholar
  5. Croxatto, H. & Belmar, J. (1961). Nature (London), 192: 879–880.Google Scholar
  6. Croxatto, H. & Belmar, J., Pereda, T. and Labarca, E. Actaphysiol. Lat. Amer., 12: 19–21.Google Scholar
  7. Ducharme, D.W., Weeks, J.R., and Montgomery, R.G., (1968). J. Pharmacol. Exp. Thar. 160: 1–10.Google Scholar
  8. Edery, H. and Lewis, G.P. (1962). Brit. J. Pharmacol. 19: 299–305.Google Scholar
  9. Emerson, T.E., Jelkes, G.W., Daugherty, R.M. and Hodgman, R.E. (1971). Am. J. Physiol., 220: 243–249.Google Scholar
  10. Guth, P.S., Bobbin, R., Cano, G. and Amaro, J. (1966). Hypotensive Peptides. Eds. Erdos, E.G., Back, N. and Sicuteri, F. p. 396, Berlin, Heidelberg and New York: Springer VerlagCrossRefGoogle Scholar
  11. Hashimoto, K., Hamamoto, H., Tijima, N. and Kumura, E. (1974). Proc. V II World Congress of Cardiology, Buenos Aires.Google Scholar
  12. Hashimoto, K., Wanka, J., Kohn, R.N., Wilkens, H.J., Steger, R. and Back, N. (1976). Kinins: Pharmacodynamics and Biological Roles. Eds. Sicuteri, F., Back, N. and Haberland, G.L. p. 245. New York: Plenum Press.CrossRefGoogle Scholar
  13. Lee, S.C. and Levine, L. (1974). J. Biol. Chem., 249: 1369–1375.Google Scholar
  14. Leslie, C.A. and Levine, L. (1973). Biochem. Biophys. Res. Comm., 52: 717–724.Google Scholar
  15. Lewis, G.P. (1963). Ann. N.Y. Acad. Sci., 104: 236–249.Google Scholar
  16. McGiff, J.C., Itskovitz, K.D., Terragno, A. and Wong, P. (1976). Fed. Proc., 35: 175–180.Google Scholar
  17. Moog, E. and Fischer, J. (1974). Arch. Exp. Path. Pharmak., 249:384–392.Google Scholar
  18. Nakano, J. (1973). Prostaglandins: Pharmacological and Therapeutic Advances. Ed. M.F. Cuthbert. p. 41. Heinemann, London.Google Scholar
  19. Northover, B.J. (1967). Brit. J. Pharmacol., 31: 483–493.Google Scholar
  20. Rowley, D.A. (1964). Brit. J. Pathol., 45: 56–67.Google Scholar
  21. Shimamoto, T., Numano, F., Fijita, T., Ishioka, T. and Atsumi, T. (1966). Hypotensive Peptides, Eds. Erdos, E.G., Back, N. and Sicuteri, F. p. 506. Berlin, Heidelberg and New York: Springer Verlag.CrossRefGoogle Scholar
  22. Terragno, D.A., Crowshaw, K., Terragno, N.A. and McGiff, J.C. (1975). Ciro. Res., 36 and 37 ( Suppl. I): 76–80.Google Scholar
  23. Terragno, N.A., Lonigro, A.J., Malik, K.U. and McGiff, J.C. (1972). Experentia, 28: 437–439.Google Scholar
  24. Tsuru, H., Ish.ikawa., N. and Shigei, T. (1974). Japn. J. Pharmacol. 24: 931.Google Scholar
  25. Wiegershausen, B. (1966). 3rd Internat. Congr. Pharmacol., Abstracts, p. 186.Google Scholar
  26. Wilkens, H.J., Back, N., Steger, R. and Karn, J. (1970). Shock: Biochemical, Pharmacological, and Clinical Aspects. Eds. Bertelli, A. and Back, N. p. 201. New York: Plenum Press.CrossRefGoogle Scholar
  27. Wilkens, H.J. and Back, N. (1974). Arch. int. Pharmacodyn., 209: 305–313.Google Scholar
  28. Wong, P.Y., Terragno, D.A., Terragno, N.A., and McGiff, J.C. (1977). Prostaglandins, 13: 1113–1125.Google Scholar

Copyright information

© Springer Science+Business Media New York 1979

Authors and Affiliations

  • Hans J. Wilkens
    • 1
  • Nathan Back
    • 1
  1. 1.Dept. Biochemical PharmacologySchool of Pharmacy State University of New YorkBuffaloUSA

Personalised recommendations